All Title Author
Keywords Abstract


DEVELOPMENT AND VALIDATION OF A RP- HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF OMEPRAZOLE AND CINITAPRIDE IN BULK AND CAPSULE DOSAGE FORM

Keywords: Cinitapride , Omeprazole , RP-HPLC , Validation.

Full-Text   Cite this paper   Add to My Lib

Abstract:

A simple reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for simultaneous determination of Omeprazole and Cinitapride in bulk and Capsule dosage form. Chromatographic analysis was performed on a Symmetry C8 column (150x 4.5 mm, 5μm) column ambient temperature with a mixture of mixed phosphate buffer and Acetonitrile in the ratio 50:50 (mixed phosphate buffer preparation; 1.625 gm of potassium Dihydrogen phosphate and 0.3 gm of Di potassium hydrogen phosphate in 550 mL HPLC grade water, pH= 6.0 adjust with phosphoric acid) as mobile phase, at a flow rate of 1.0 mL min-1. UV detection was performed at 287 nm. The method was validated for accuracy, precision, specificity, linearity and sensitivity. The retention times of Omeprazole and Cinitapride were 2.49 and 3.650 min, respectively. Calibration plots were linear over the concentration ranges 5–30 μg mL-1 and 0.75-4.5 μg mL-1 for Omeprazole and Cinitapride, respectively. The Limit of detection was 1.43570 and 0.086 μg mL-1 and the quantification limit was 4.35 μg mL-1 and 0.26 μg mL-1 for Omeprazole and Cinitapride, respectively. The accuracy of the proposed method was determined by recovery studies and found to be 98.62% to 100.37%. Commercial capsule formulation was successfully analyzed using the developed method and the proposed method is applicable to routine analysis of determination of Omeprazole and Cinitapride in bulk and capsule dosage form.

Full-Text

comments powered by Disqus